The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells.

In this study, the downstream signaling of Bcr-Abl tyrosine kinase responsible for apoptosis resistance was investigated. DNA fragmentation, a hallmark of apoptosis, was observed after 2 days of herbimycin A treatment with a peak on 3 day. During the apoptosis induced by the treatment of herbimycin A, stress-activated protein kinase (SAPK) and p38 kinase were activated time- and dose-dependently, while extracellular signal-regulated kinase (ERK) was inhibited. However, apoptosis was induced by the treatment of PD98059, a specific inhibitor of MEK (MAPK or ERK kinase), not by the treatment of sorbitol, a strong activator of SAPK and p38 kinase. Although K562 cells were very resistant to sorbitol-induced apoptosis, DNA fragmentation was induced rapidly in Jurkat, HL-60 and U937 cells after exposure to sorbitol, despite that these apoptosis-sensitive cells have similar or lower activities of JNK/SAPK and p38 kinase compared with K562 cells after treatment of sorbitol. K562 cells had a much higher basal activity of ERK/MAPK than other apoptosis-sensitive cell lines, which were very susceptible to apoptosis induced by low dose of PD98059 compared with K562 cells. In HL-60 cells, sorbitol-induced apoptosis was prevented by the treatment of phorbol myristate 13-acetate (PMA), which activates the ERK/MAPK pathway, and this was blocked by PD98059. From these results, it could be suggested that the inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in K562 cells.

[1]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[2]  Y. Pommier,et al.  The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. , 1995, Leukemia.

[3]  E. Buchdunger,et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.

[4]  L. Rubin,et al.  Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons , 1998, The Journal of Neuroscience.

[5]  T. Hambuch,et al.  The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Cortez,et al.  A requirement for NF-κB activation in Bcr–Abl-mediated transformation , 1998 .

[7]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[8]  D. Cortez,et al.  The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells , 1997, Oncogene.

[9]  E. Goillot,et al.  Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Bonavida,et al.  Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. , 1989, The Journal of biological chemistry.

[11]  D. Cortez,et al.  The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. , 1996, Oncogene.

[12]  Seamus J. Martin,et al.  Regulation of the Fas Apoptotic Cell Death Pathway by Abl (*) , 1995, The Journal of Biological Chemistry.

[13]  D. Green,et al.  Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. , 1998, Blood.

[14]  Michel Morange,et al.  A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins , 1994, Cell.

[15]  G. Johnson,et al.  Sequential protein kinase reactions controlling cell growth and differentiation. , 1994, Current opinion in cell biology.

[16]  E. Krebs,et al.  The MAPK signaling cascade , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  J. Hsuan,et al.  Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of hsp27 , 1994, Cell.

[18]  C. Sawyers,et al.  Signal transduction by wild-type and leukemogenic Abl proteins. , 1997, Biochimica et biophysica acta.

[19]  Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis , 1997 .

[20]  K. Bhalla,et al.  Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[21]  W. El-Deiry,et al.  BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. , 1995, Blood.

[22]  Xiantao Wang,et al.  Dopamine Induces Apoptosis through an Oxidation-involved SAPK/JNK Activation Pathway* , 1998, The Journal of Biological Chemistry.

[23]  Jiahuai Han,et al.  Pro-inflammatory Cytokines and Environmental Stress Cause p38 Mitogen-activated Protein Kinase Activation by Dual Phosphorylation on Tyrosine and Threonine (*) , 1995, The Journal of Biological Chemistry.

[24]  E. Krebs,et al.  Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mIgM-induced apoptosis of human B lymphocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  N. Davidson,et al.  Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. , 1993, Cancer research.

[26]  D. Leroith,et al.  Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase Pathways* , 1997, The Journal of Biological Chemistry.

[27]  O. Witte.  Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture. , 1993, Cancer research.

[28]  G. Johnson,et al.  Fibroblast Growth Factor-2 Suppression of Tumor Necrosis Factor α-Mediated Apoptosis Requires Ras and the Activation of Mitogen-activated Protein Kinase* , 1996, Journal of Biological Chemistry.

[29]  E. Solary,et al.  BCR-ABL delays apoptosis upstream of procaspase-3 activation. , 1998, Blood.

[30]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[31]  M. Campbell,et al.  Inhibition of phosphorylation of p160 BCR within p210 BCR-ABL complexes during early stages of phorbol ester-induced differentiation of K562 cells. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[32]  R. Davis,et al.  The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. , 1996, The Journal of biological chemistry.

[33]  D. Green,et al.  Bcr – Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity , 1997, Cell Death and Differentiation.

[34]  C. Kuo,et al.  Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases , 1997, Molecular and cellular biology.

[35]  J. Avruch,et al.  Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation* , 1996, The Journal of Biological Chemistry.

[36]  A. Whetton,et al.  v-Abl-mediated Apoptotic Suppression Is Associated with SHC Phosphorylation without Concomitant Mitogen-activated Protein Kinase Activation (*) , 1995, The Journal of Biological Chemistry.

[37]  P. Rowley,et al.  The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. , 1996, Leukemia research.

[38]  A. Kong,et al.  Molecular Mechanisms of c-Jun N-terminal Kinase-mediated Apoptosis Induced by Anticarcinogenic Isothiocyanates* , 1998, The Journal of Biological Chemistry.

[39]  L. Wiedemann,et al.  A temperature sensitive p210 BCR‐ABL mutant defines the primary consequences of BCR‐ABL tyrosine kinase expression in growth factor dependent cells. , 1994, The EMBO journal.

[40]  T. Tsuruo,et al.  c-Jun NH2-terminal Kinase-mediated Activation of Interleukin-1β Converting Enzyme/CED-3-like Protease during Anticancer Drug-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[41]  T. Tsuruo,et al.  Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148 , 1998, Cell Death and Differentiation.

[42]  L. Heasley,et al.  c-Jun NH2-terminal Kinase Regulation of the Apoptotic Response of Small Cell Lung Cancer Cells to Ultraviolet Radiation* , 1997, The Journal of Biological Chemistry.

[43]  L. Zon,et al.  Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis , 1996, Nature.

[44]  D. Green,et al.  BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death , 1994 .

[45]  B. Zehnbauer,et al.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.